Arimoclomol for the treatment of Niemann-Pick disease type C in a real-world setting: long-term outcomes from an expanded access program in the United States
Tuesday, September 9, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The article discusses the long-term outcomes of Arimoclomol for treating Niemann-Pick disease type C, based on data from an expanded access program in the United States. The findings were presented at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025. The results indicate a positive impact of the treatment in a real-world setting.
Price reaction · baseline $8.33 (2025-09-08 close) · hit pre-market · 2 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
Arimoclomol shows promise in treating Niemann-Pick disease type C.
Long-term outcomes from the expanded access program are encouraging.
The study highlights real-world effectiveness of the treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol for the treatment of Niemann-Pick disease type C in a real-world setting: long-term outcomes from an expanded access program in the United States
International Congress of Inborn Errors of Metabolism (ICIEM) 2025 - 09/04/2025
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is used for treating Niemann-Pick disease type C.
What were the outcomes of the expanded access program?
The outcomes indicated a positive long-term impact of Arimoclomol.
When was the study presented?
The study was presented at the International Congress of Inborn Errors of Metabolism in 2025.
What is Niemann-Pick disease type C?
Niemann-Pick disease type C is a rare genetic disorder affecting lipid metabolism.